Revvity will acquire ACD/Labs to strengthen its signals software offerings. The signals software move aims to improve scientific informatics. This signals software deal combines spectral analysis and molecular design tools into one platform.
Strategic Fit and Scope
Moreover, Revvity expects to integrate ACD/Labs’ Spectrus® platform for spectral analysis. Consequently, teams can analyze chemical data faster and with more accuracy. In addition, Percepta® and other ACD/Labs tools will support molecular design and property prediction. Therefore, researchers will benefit from tighter workflows and faster insight.
Business Impact and Outlook
Furthermore, Revvity already serves discovery, development, and manufacturing markets. By adding ACD/Labs, the company strengthens enterprise analytical data management. As a result, customers gain improved cloud workflows and better decision support. Moreover, the combined stack targets pharma, materials science, and chemical R&D. The companies expect the deal to close in late Q4 2025, subject to approvals and closing conditions.
In short, this acquisition signals a clear move toward integrated scientific informatics. Moreover, it highlights how software-first solutions can speed research. Therefore, companies in life sciences and chemical research should watch how this integration unfolds. For now, Revvity aims to deliver a unified platform that improves analysis, design, and manufacturing workstreams.
Looking for more updates on financial innovation and revenue-driven technology? Visit RevTech News for expert insights and the latest trends.
News Source: Businesswire.com
